Navigation Links
Amicus Therapeutics Announces Third Quarter 2010 Financial Results
Date:11/8/2010

CRANBURY, N.J., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the quarter ended September 30, 2010, provided an update on its product development pipeline, including its Phase 3 program with Amigal (migalastat HCl) for the treatment of Fabry disease and reaffirmed the financial strength of the Company.  

John F. Crowley, Chairman and CEO of Amicus Therapeutics stated, "During the third quarter we made significant progress further establishing Amicus as a leader in the research and development of new treatments for rare diseases.  Our strategic partnership with GSK not only supports the potential for success with the Amigal program but also provides us with multiple strategic options for continued growth.  Moving forward, we intend to judiciously invest in our pipeline and to explore a series of additional partnerships, all while ensuring that our financial strength allows us to fund our operations and capital expenditures through the anticipated U.S. commercial launch of Amigal."

Third Quarter Financial SummaryAs of September 30, 2010, Amicus held $57.6 million of cash, cash equivalents, and marketable securities.

For the three months ended September 30, 2010, Amicus reported a net loss of $15.4 million, or $0.56 per share attributable to common stockholders, compared to a net loss of $13.4 million, or $0.59 per share attributable to common stockholders for the same period in 2009.

Pipeline OverviewAmigal (migalastat HCl) for the Treatment of Fabry DiseaseOn October 29, 2010, Amicus announced a definitive agreement with GlaxoSmithKline PLC (GSK) to develop and commercialize Amigal™ (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease.  Under the terms of the agreement, GSK received an exclusive worldwide license to d
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
2. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
3. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
4. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
5. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
6. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
7. Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
8. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
9. Amicus Therapeutics Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
10. Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... SOUTH PLAINFIELD, N.J. , July 24, 2014 /PRNewswire/ ... announced that the Company will host a webcast conference ... and provide an update on the company,s business and ... (ET) before the opening of the market. ... 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
(Date:7/24/2014)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today reported ... ended June 30, 2014.  Global revenue for ... 19% to $4.1 million, as compared to $3.4 ... year.  Total revenue for the fiscal first quarter ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... Ga., Nov. 8, 2011 GeckoSystems International Corporation (Pink ... announced today that they have successfully completed Alpha testing ... is a leader in the emerging mobile robotics industry, ... Security and Service™. "We are very ...
... International Isotopes Inc. (OTC Bulletin Board: INIS), a leading ... announce it has completed an agreement in principle ... for the production of Copper-67.  Copper-67 has shown ... as well as bladder, colorectal, and ovarian cancers. ...
Cached Medicine Technology:GeckoSystems Successfully Applies Its Mobile Robot Solutions to Improve Wheelchair Safety 2GeckoSystems Successfully Applies Its Mobile Robot Solutions to Improve Wheelchair Safety 3GeckoSystems Successfully Applies Its Mobile Robot Solutions to Improve Wheelchair Safety 4GeckoSystems Successfully Applies Its Mobile Robot Solutions to Improve Wheelchair Safety 5International Isotopes Inc. Announces the Completion of an Agreement in Principle With Idaho State University for the Production of Copper-67 for Experimental Use in Cancer Treatment 2International Isotopes Inc. Announces the Completion of an Agreement in Principle With Idaho State University for the Production of Copper-67 for Experimental Use in Cancer Treatment 3International Isotopes Inc. Announces the Completion of an Agreement in Principle With Idaho State University for the Production of Copper-67 for Experimental Use in Cancer Treatment 4
(Date:7/24/2014)... Ariz. July 24, 2014 A new study ... insights into the interplay among bacteria, viruses and the ... HIV-positive men,s infectivity their potential to infect others ... men produce large amounts of virus in their semen ... this "compartmentalization," where different levels of the virus can ...
(Date:7/24/2014)... London, UK (PRWEB) July 24, 2014 Memantine ... and was first marketed in Germany under the brand name ... and other nations as Ebixa and in the USA to ... of USD 420 million in 2013. In the US, Forest ... , Patent protection expiry in Canada, Australia and the European ...
(Date:7/24/2014)... IA (PRWEB) July 24, 2014 Members of ... Michael Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, ... Governor appointed him to the Board and that his peers ... “I want to provide the best I can for the ... I am uniquely positioned to provide a special insight to ...
(Date:7/24/2014)... In a recent report by CBS News, the district capital ... criminal penalties associated with possession of small amounts of marijuana. ... Washington DC, giving it one of the most tolerant marijuana ... possession of one ounce of marijuana or less with a ... an ounce of marijuana remain criminal offenses under the new ...
(Date:7/24/2014)... women who received the Human Papillomavirus Vaccination (HPV) ... of abnormal Pap test results than those who ... journal Sexually Transmitted Diseases . , ... and School of Medicine conducted a cross-sectional study ... routine cervical cytology testing. HPV status and demographic ...
Breaking Medicine News(10 mins):Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Washington D.C. Decriminalizes Marijuana 2
... to Local Seniors, SAN FRANCISCO, June 10 ... to exercise their brains through the Brain Fitness ... partnership with San,Francisco-based Posit Science. The Brain Fitness ... memory and other cognitive functions,with participants reporting they ...
... addiction affordable, study says , , TUESDAY, June 10 ... have declined in recent years, but sales of non-cigarette ... cigarette sales by 30 percent, a Harvard School of ... data and found that between 2000 and 2007, cigarette ...
... expenses for chemotherapy may affect treatment decisions, expert ... Costs for treating Medicare patients with cancer increased ... The upward trend, seen with breast, lung and ... more patients are receiving radiation and chemotherapy, and ...
... popularity of golf carts has skyrocketed in recent years, ... injuries. In fact, a new study conducted by researchers ... The Research Institute at Nationwide Children,s Hospital found that ... during the 17-year study period. , According to ...
... June 10 Syneron(TM) Medical,Ltd. (Nasdaq: ... marketing and sales,of elos(TM) combined-energy medical aesthetic ... with Sono Bello Body Contouring,Centers for its ... thigh circumferential reduction device., Sono Bello ...
... CHAPEL HILL, N.C., June 10 Highly ... turnover and boost,corporate performance reside in less ... member-driven research study conducted by Best Practices,LLC,s ... satisfaction and engagement metrics and,ensure employees know ...
Cached Medicine News:Health News:30th Street Senior Center and Posit Science Put Their Heads Together On New Program 2Health News:30th Street Senior Center and Posit Science Put Their Heads Together On New Program 3Health News:Decline in Cigarette Sales Offset by Use of Alternative Products 2Health News:Medicare Costs for Cancer Treatment Soar 2Health News:Medicare Costs for Cancer Treatment Soar 3Health News:First national study to examine golf cart-related injuries 2Health News:Syneron Signs Multi-Year Exclusive Equipment Provider Agreement with Sono Bello Body Contouring Centers to Offer LipoLite(TM) and VelaShape(TM) 2Health News:Syneron Signs Multi-Year Exclusive Equipment Provider Agreement with Sono Bello Body Contouring Centers to Offer LipoLite(TM) and VelaShape(TM) 3Health News:Best-in-Class Engagement Programs: Employees See Link Between Quality & Performance 2
Volume: 2 ml; Volume Graduation: 1/100 ml...
... PipetBoy Pipettor is light as a feather and ... speed can be continuously adjusted. The pipette mount ... autoclaved. Two dosing knobs enable fine dosing to ... an/or glass pipettes from 0.1 to 100 ml. ...
Precise, safe, and fatigue-free series pipetting using graduated pip...
Inquire...
Medicine Products: